Therapeutic Contact Intensity in a Psychological Smoking Cessation Intervention With an App
Launched by UNIVERSITY OF SANTIAGO DE COMPOSTELA · Mar 21, 2025
Trial Information
Current as of April 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how different levels of support can help people quit smoking using a mobile app. Participants will be divided into three groups: one group will have eight sessions with trained psychologists and access to the app, the second group will have four sessions with psychologists and the app, while the last group will only use the app without any sessions. The goal is to see how these different levels of support affect how successfully people can stop smoking.
To join the study, participants need to be at least 18 years old, want to quit smoking, and smoke at least five cigarettes a day. They also need to have a smartphone and be willing to use it during the treatment. However, individuals with certain serious mental health issues, those who use other tobacco products, or who have recently received other treatments to quit smoking may not be eligible. This trial is not yet recruiting participants, but it aims to find out what type of support works best for people trying to quit smoking.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • aged 18 or over
- • wishing to participate in the treatment
- • providing written informed consent
- • smoking at least 5 cigarettes per day
- • completion of all pre-treatment assessment questionnaires
- • having a valid email address
- • having an Android or iOS smartphone and being willing to use it throughout the treatment
- Exclusion Criteria:
- • a diagnosis of severe mental disorder (bipolar disorder and/or psychotic disorder)
- • concurrent substance use disorder (alcohol, cannabis, stimulant, hallucinogen and/or opioid)
- • using other tobacco products (electronic cigarette with nicotine, cigars or cigarillos)
- • having completed an effective psychological treatment to quit smoking during the previous year
- • having completed a pharmacological treatment to quit smoking in the last year (any smoking cessation medication approved by the Agencia Española del Medicamento)
- • having a physical pathology involving high vital risk that requires immediate intervention (e.g., recent myocardial infarction)
- • having visual difficulties that prevent the use of the App.
About University Of Santiago De Compostela
The University of Santiago de Compostela, a prestigious institution located in Spain, is dedicated to advancing scientific research and healthcare through innovative clinical trials. With a rich history of academic excellence, the university fosters a multidisciplinary approach, bringing together experts in medicine, pharmacology, and public health to conduct rigorous studies aimed at improving patient outcomes. Committed to ethical practices and the highest standards of research integrity, the university collaborates with various stakeholders, including healthcare providers and industry partners, to translate findings into real-world applications that enhance medical knowledge and treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Santiago De Compostela, A Coruña, Spain
Patients applied
Trial Officials
Ana López-Durán, Phd.
Principal Investigator
University of Santiago de Compostela
Elisardo Becoña Iglesias, Phd.
Principal Investigator
University of Santiago de Compostela
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported